Tissue and serum levofloxacin concentrations in diabetic foot infection patients

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 4, 2004, Pages 836-839

  Oberdorfer, Klaus ^a   Swoboda, S ^a   Hamann, A ^a   Baertsch, U ^a   Kusterer, K ^b   Born, B ^c   Hoppe Tichy, T ^a   Geiss, H K ^a   von Baum, H ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Outpatient Practice   (Germany)

^c Klinikum am Steinenberg   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Diabetic foot infections; MRSA; Pharmacokinetics; Quinolones; Soft tissue infections

Indexed keywords

ANTACID AGENT; FENBUFEN; INSULIN; LEVOFLOXACIN; MAGNESIUM; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUCRALFATE; THEOPHYLLINE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; FLUORESCENCE ANALYSIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OUTPATIENT DEPARTMENT; TISSUE NECROSIS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETIC FOOT; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; TISSUE DISTRIBUTION;

EID: 6344277283     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh412     Document Type: Article

References (12)

1. Boulton, A. J., Meneses, P. & Ennis, W. J. (1999). Diabetic foot ulcers: a framework for prevention and care. Wound Repair and Regeneration 7, 7-16.
2. Louie, T. J., Bartlett, J. G., Tally, F. P. et al. (1976). Aerobic and anaerobic bacteria in diabetic foot ulcers. Annals of Internal Medicine 85, 461-3.
3. Fish, D. N. & Chow, A. T. (1997). The clinical pharmocokinetics of levofloxacin. Clinical Pharmacokinetics 32, 101-19.
4. Wagner, F. W. Jr (1981). The dysvascular foot: a system of diagnosis and treatment. Foot & Ankle 2, 64-122.
5. Boettcher, S., von Baum, H., Hoppe-Tichy, T. et al. (2001). An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum. Journal of Pharmaceutical and Biomedical Analysis 25, 197-203.
6. Swoboda, S., Oberdorfer, K., Klee, F. et al. (2003). Tissue and serum concentration of levofloxacin 500 mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery. Journal of Antimicrobial Chemotherapy 51, 459-62.
7. Kuck, E. M., Bouter, K. P., Hoekstra, J. B. et al. (1998). Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections. Foot & Ankle International 19, 38-40.
8. Mueller-Buehl, U., Diehm, C., Gutzler, F. et al. (1991). Tissue concentrations of ofloxacin in necrotic foot lesions of diabetic and non-diabetic patients with peripheral arterial occlusive disease. Vasa 20, 17-21.
9. Chow, A. T., Chen, A., Lattime, H. et al. (2002). Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. Journal of Clinical Pharmacy and Therapeutics 27, 143-50.
10. Lipsky, B. A., Bakter, P. D., Landon, G. C. et al. (1997). Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clinical Infectious Diseases 24, 643-8.
11. Graham, D. R., Talan, D. A., Nichols, R. L. et al. (2002). Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxycillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clinical Infectious Disease 35, 381-9.
12. Weber, S., Gold, H. S., Hooper, D. C. et al. (2003). Fluoroquinolones and the risk for Methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerging Infectious Diseases 9, 1415-21.